

June 13, 2019



# Lexaria Bioscience Corp. Featured in CannabisNewsAudio Broadcast on Dramatic Results of CBD Delivery System Study

NEW YORK, June 13, 2019 (GLOBE NEWSWIRE) -- via CannabisNewsAudio – [Lexaria Bioscience Corp. \(CSE: LXX\) \(OTCQX: LXRP\)](#) today announces the availability of an audio press release titled, “Dramatically Improved Delivery Systems Promise More Effective Cannabis Treatments.”

To hear the CannabisNewsAudio version, visit: <http://cnw.fm/My9kX>.

To read the full editorial, visit: <http://cnw.fm/O5Oes>.

A biotech company based in British Columbia, [Lexaria Bioscience Corp. \(CSE: LXX\) \(OTCQX:LXRP\)](#) is currently focusing on its proprietary DehydraTECH(TM) technology. This unique technology has been developed to make medicinal compounds more suitable for human consumption in a number of ways. By combining molecules such as CBD with fatty acids at a molecular level, DehydraTECH makes it easier for the CBD to cross the body’s internal barriers. Higher levels of CBD are absorbed, and they are absorbed more quickly.

Consumers need to know this: the quantity of CBD, or any other drug, in the bottle is unimportant. What matters is how much of that CBD actually reaches the bloodstream — and even more importantly — how much reaches the brain.

[LXRP study] results announced in May showed that DehydraTECH, in combination with generic nanotech techniques, [delivered CBD to the brain 1,137% more efficiently](#) than existing industry formulations.

## About Lexaria Bioscience Corp.

Lexaria Bioscience has developed and out-licenses its disruptive delivery technology, which promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the United States and Australia for utilization of its DehydraTECH delivery technology. Lexaria’s technology provides increases in intestinal absorption rates, more rapid delivery to the bloodstream, and important taste-masking benefits for orally administered bioactive molecules including cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. For more information, visit the company’s website at [www.LexariaBioscience.com](http://www.LexariaBioscience.com).

## **About CannabisNewsWire (CNW)**

CannabisNewsWire (“CNW”) is a specialized information service that (1) aggregates cannabis news, (2) provides [CannabisNewsBreaks](#) that quickly updates investors in the space, (3) enhances corporate press releases, (4) helps companies with distribution and optimization of social media, and (5) delivers comprehensive corporate communication solutions. CNW is uniquely positioned in the cannabis market with a strong team of journalists and writers who can help private and public companies reach a wide audience of investors, consumers, journalists and the general public through our ever-growing dissemination network of more than 5,000 key syndication outlets. CNW is bringing unparalleled visibility, recognition and content to the cannabis industry.

For more information please visit <https://www.CannabisNewsWire.com>.

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published:  
<http://CNW.fm/Disclaimer>.

## **Forward-Looking Statements**

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

## **Corporate Communications:**

CannabisNewsWire (CNW)  
Denver, Colorado  
[www.CannabisNewsWire.com](http://www.CannabisNewsWire.com)  
303.498.7722 Office  
[Editor@CannabisNewsWire.com](mailto:Editor@CannabisNewsWire.com)



Source: Lexaria Bioscience Corp.